This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hussain, S. F. Articles by Heimberger, A. B. Search for Related Content PubMed PubMed Citation Articles by Hussain, S. F. Articles by Heimberger, A. B.

A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients

Departments of ¹ Neurosurgery, ² Neuro-oncology, and ³ Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Amy B. Heimberger, Department of Neurosurgery, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-2400; Fax: 713-794-4950; E-mail: aheimber{at}mdanderson.org and Waldemar Priebe, Department of Experimental Therapeutics, Unit 422, 1515 Holcombe Boulevard, Houston TX 77030; E-mail: wpreibe{at}mdanderson.org.

Overcoming the profound immunosuppression in patients with solid cancers has impeded efficacious immunotherapy. Signal transducers and activators of transcription 3 (STAT3) has recently emerged as a potential target for effective immunotherapy, and in this study, we describe a novel small molecule inhibitor of STAT3 that can penetrate the central nervous system (CNS) in mice and in physiologically relevant doses in vitro and reverse tolerance in immune cells isolated from glioblastoma multiforme (GBM) patients. Specifically, it induces the expression of costimulatory molecules on peripheral macrophages and tumor-infiltrating microglia, stimulates the production of the immune-stimulatory cytokines interleukin 2 (IL-2), IL-4, IL-12, and IL-15, and induces proliferation of effector T cells from GBM patients that are refractory to CD3 stimulation. We show that the functional enhancement of immune responses after STAT3 inhibition is accompanied by up-regulation of several key intracellular signaling molecules that critically regulate T-cell and monocyte activation. Specifically, the phosphorylation of Syk (Tyr³⁵²) in monocytes and ZAP-70 (Tyr³¹⁹) in T cells are enhanced by the STAT-3 inhibitor in marked contrast to toll-like receptor and T-cell receptor agonists, respectively. This novel small molecule STAT3 inhibitor has tremendous potential for clinical applications with its penetration into the CNS, easy parental administration, direct tumor cytotoxicity, and potent immune adjuvant responses in immunosuppressed cancer patients. [Cancer Res 2007;67(20):9630–6]

This article has been cited by other articles:

				M. E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L. M. HERBERT, and D. M. LOPEZ Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors Anticancer Res, June 1, 2009; 29(6): 2051 - 2058. [Abstract] [Full Text] [PDF]

				W. A. Messersmith, N.V. Rajeshkumar, A. C. Tan, X. F. Wang, V. Diesl, S. E. Choe, M. Follettie, C. Coughlin, F. Boschelli, E. Garcia-Garcia, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts Mol. Cancer Ther., June 1, 2009; 8(6): 1484 - 1493. [Abstract] [Full Text] [PDF]

				M. Z. Noman, S. Buart, J. Van Pelt, C. Richon, M. Hasmim, N. Leleu, W. M. Suchorska, A. Jalil, Y. Lecluse, F. El Hage, et al. The Cooperative Induction of Hypoxia-Inducible Factor-1{alpha} and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis J. Immunol., March 15, 2009; 182(6): 3510 - 3521. [Abstract] [Full Text] [PDF]

				R. P. Sahu and S. K. Srivastava The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate J Natl Cancer Inst, February 4, 2009; 101(3): 176 - 193. [Abstract] [Full Text] [PDF]

				M. Abou-Ghazal, D. S. Yang, W. Qiao, C. Reina-Ortiz, J. Wei, L.-Y. Kong, G. N. Fuller, N. Hiraoka, W. Priebe, R. Sawaya, et al. The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas Clin. Cancer Res., December 15, 2008; 14(24): 8228 - 8235. [Abstract] [Full Text] [PDF]

				A. M. Kostianovsky, L. M. Maier, R. C. Anderson, J. N. Bruce, and D. E. Anderson Astrocytic Regulation of Human Monocytic/Microglial Activation J. Immunol., October 15, 2008; 181(8): 5425 - 5432. [Abstract] [Full Text] [PDF]

				L.-Y. Kong, M. K. Abou-Ghazal, J. Wei, A. Chakraborty, W. Sun, W. Qiao, G. N. Fuller, I. Fokt, E. A. Grimm, R. J. Schmittling, et al. A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells Clin. Cancer Res., September 15, 2008; 14(18): 5759 - 5768. [Abstract] [Full Text] [PDF]

				E. C. Brantley and E. N. Benveniste Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas Mol. Cancer Res., May 1, 2008; 6(5): 675 - 684. [Abstract] [Full Text] [PDF]

				M. Fujita, X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma J. Immunol., February 15, 2008; 180(4): 2089 - 2098. [Abstract] [Full Text] [PDF]